Cargando…
Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage
INTRODUCTION: The transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875788/ https://www.ncbi.nlm.nih.gov/pubmed/29596469 http://dx.doi.org/10.1371/journal.pone.0194989 |
_version_ | 1783310411945213952 |
---|---|
author | Thierauf, Julia Weissinger, Stephanie E. Veit, Johannes A. Affolter, Annette Laureano, Natalia K. Beutner, Dirk Heiduschka, Gregor Kadletz, Lorenz Meyer, Moritz Quaas, Alexander Plinkert, Peter Hoffmann, Thomas K. Hess, Jochen |
author_facet | Thierauf, Julia Weissinger, Stephanie E. Veit, Johannes A. Affolter, Annette Laureano, Natalia K. Beutner, Dirk Heiduschka, Gregor Kadletz, Lorenz Meyer, Moritz Quaas, Alexander Plinkert, Peter Hoffmann, Thomas K. Hess, Jochen |
author_sort | Thierauf, Julia |
collection | PubMed |
description | INTRODUCTION: The transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognostic value appears to be highly context dependent. As an example, high SOX2 expression in lung squamous cell carcinoma (SCC) is related to a favorable prognosis, while it is associated with poor outcome in lung adenocarcinoma. More recently, higher SOX2 levels and improved survival was also reported for head and neck SCC (HNSCC), and silencing of SOX2 expression in HNSCC cell lines revealed a mesenchymal-like phenotype with prominent vimentin expression. So far, SOX2 expression and its clinical relevance for other head and neck cancers, such as adenoid cystic carcinoma (HNACC) have not been sufficiently investigated. MATERIAL AND METHODS: SOX2, vimentin and E-cadherin expression was assessed by immunohistochemical staining on serial sections from formalin fixed and paraffin embedded tissue samples of a patient cohort (n = 45) with primary ACC and correlated with patient and tumor characteristics as well as survival. RESULTS: High SOX2 expression was found in 14 (31%) primary tumor specimens and was significantly correlated with a N0 lymph node status (p = 0.04), while low SOX2 expression was correlated with a solid growth pattern (p = 0.031). Of the 45 patients, 27 tumor samples resembled an EMT-like phenotype, as assessed by high vimentin and low E-cadherin levels. However, in HNACC SOX2 levels were neither correlated with vimentin nor with E-cadherin expression, further supporting a context dependent regulation and function of SOX2 in distinct tumor entities. CONCLUSION: The absence of SOX2 was predominantly found in solid HNACC, which are characterized by a more aggressive phenotype in ACC. However, the underlying molecular mechanisms of SOX2 regulation and function in distinct HNACC subgroups remain to be fully elucidated. |
format | Online Article Text |
id | pubmed-5875788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-58757882018-04-13 Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage Thierauf, Julia Weissinger, Stephanie E. Veit, Johannes A. Affolter, Annette Laureano, Natalia K. Beutner, Dirk Heiduschka, Gregor Kadletz, Lorenz Meyer, Moritz Quaas, Alexander Plinkert, Peter Hoffmann, Thomas K. Hess, Jochen PLoS One Research Article INTRODUCTION: The transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognostic value appears to be highly context dependent. As an example, high SOX2 expression in lung squamous cell carcinoma (SCC) is related to a favorable prognosis, while it is associated with poor outcome in lung adenocarcinoma. More recently, higher SOX2 levels and improved survival was also reported for head and neck SCC (HNSCC), and silencing of SOX2 expression in HNSCC cell lines revealed a mesenchymal-like phenotype with prominent vimentin expression. So far, SOX2 expression and its clinical relevance for other head and neck cancers, such as adenoid cystic carcinoma (HNACC) have not been sufficiently investigated. MATERIAL AND METHODS: SOX2, vimentin and E-cadherin expression was assessed by immunohistochemical staining on serial sections from formalin fixed and paraffin embedded tissue samples of a patient cohort (n = 45) with primary ACC and correlated with patient and tumor characteristics as well as survival. RESULTS: High SOX2 expression was found in 14 (31%) primary tumor specimens and was significantly correlated with a N0 lymph node status (p = 0.04), while low SOX2 expression was correlated with a solid growth pattern (p = 0.031). Of the 45 patients, 27 tumor samples resembled an EMT-like phenotype, as assessed by high vimentin and low E-cadherin levels. However, in HNACC SOX2 levels were neither correlated with vimentin nor with E-cadherin expression, further supporting a context dependent regulation and function of SOX2 in distinct tumor entities. CONCLUSION: The absence of SOX2 was predominantly found in solid HNACC, which are characterized by a more aggressive phenotype in ACC. However, the underlying molecular mechanisms of SOX2 regulation and function in distinct HNACC subgroups remain to be fully elucidated. Public Library of Science 2018-03-29 /pmc/articles/PMC5875788/ /pubmed/29596469 http://dx.doi.org/10.1371/journal.pone.0194989 Text en © 2018 Thierauf et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Thierauf, Julia Weissinger, Stephanie E. Veit, Johannes A. Affolter, Annette Laureano, Natalia K. Beutner, Dirk Heiduschka, Gregor Kadletz, Lorenz Meyer, Moritz Quaas, Alexander Plinkert, Peter Hoffmann, Thomas K. Hess, Jochen Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage |
title | Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage |
title_full | Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage |
title_fullStr | Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage |
title_full_unstemmed | Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage |
title_short | Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage |
title_sort | low sox2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875788/ https://www.ncbi.nlm.nih.gov/pubmed/29596469 http://dx.doi.org/10.1371/journal.pone.0194989 |
work_keys_str_mv | AT thieraufjulia lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT weissingerstephaniee lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT veitjohannesa lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT affolterannette lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT laureanonataliak lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT beutnerdirk lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT heiduschkagregor lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT kadletzlorenz lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT meyermoritz lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT quaasalexander lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT plinkertpeter lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT hoffmannthomask lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage AT hessjochen lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage |